Elacestrant not checked

Stemline Therapeutics, Inc. · RAD1901 · ER-306323

FollowEvery change as it happens, and a Monday email
Stage
in the US · approved in the EU
Next date
Phase 2 trial completes
Trials
16 active
20 in total · 15 in the EU

What this is

How it works
Blocks oestrogen from acting on cells. Used against breast cancer that oestrogen feeds.Estrogen Receptor Antagonist FDA class
How it’s given
“Starting dose 400 mg elacestrant dihydrochloride administered orally once daily for an estimated 6 months of treatment.”In the company’s words, NCT05596409 on ClinicalTrials.gov
Tested for
Breast Cancer (3 trials), Metastatic Breast Cancer (2 trials), Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms and 3 more
Main trialPhase 3
“The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.”In the company’s words, NCT06492616 on ClinicalTrials.gov
Other names
RAD1901 · ORSERDU · ER-306323

Other drugs for Breast Cancer

All 396 drugs for Breast Cancer

Coming up6

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials20

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting Aug 2029 A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Phase 2Active, not recruiting Nov 2026 ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study
Phase 2Recruiting Oct 2028 A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer
Phase 1/2Active, not recruiting 27 Dec 2026 Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
Phase 1/2Recruiting Dec 2026 Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Phase 1Recruiting 24 Oct 2027 A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
Phase 3Completed 24 Aug 2021 Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Phase 1Completed 30 Aug 2018 Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer
Phase 1Completed Sep 2019 A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer
Phase 1Completed 11 Nov 2024 A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic Function
Phase 3Authorised not given EORTC 2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA)
Phase 2Authorised not given Phase II, multicenter, randomized, open-label study of premenopausal women with luminal breast cancer investigating the effect of oral SERD elacestrant with/without triptorelin in the ER functional pathway and Ki67 proliferation. Preoperative trial – PremiÈRe
Phase 2Authorised not given Phase II study evaluating the addition of elacestrant, an oral selective estrogen receptor degrader (SERD), to standard-of-care olaparib in patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with gBRCA1/2 mutations – ELEMENT
Phase 2Authorised not given ABCSG 63 / ERIKA: Elacestrant and RIbociclib in Ki67-tested endocrine responsive breAst cancer: An open-label, two-arm, randomized, phase II study of elacestrant plus ribociclib vs. AI (plus GnRH agonist in pre-/perimenopausal women and men) plus ribociclib as neoadjuvant therapy for endocrine-responsive HER2-negative early breast cancer
Phase 3Authorised not given A randomized phase 3, double-blind, placebo-controlled study of elacestrant plus everolimus versus elacestrant in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced breast cancer progressing to endocrine therapy and CDK4/6 inhibitors - The ADELA study-
Phase 2Authorised not given Elacestrant and exemestane for patients with pretreated HR+/HER2- metastatic breast cancer and [18F]-FES-avid lesions (COMBINE): a proof-of-concept phase 2 clinical trial
Phase 2Authorised not given POP-ELA: A short-term preoperative, window-of-opportunity study, evaluating activity and safety of Elacestrant monotherapy as compared to Elacestrant + ovarian function suppression (LHRH agonist) in premenopausal patients with stage I-II ER+/HER2- breast cancer
Phase 2Authorised not given Hormonal Receptor (HR)-positive HER2 negative breast cancer patients treated with preoperative ELacestrant and PULSAR adaptive radiotherapy: a phase II study
Phase 3Authorised not given Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing adjuvant Elacestrant with standard endocrine treatment in genomically and/or clinically high-risk ER+/HER2- early breast cancer (ADAPTela)
Phase 2Authorised not given A multicenter, multicohort, phase 2 platform trial to personalize second-line treatment intensity and targeting in HR-positive, HER2-negative metastatic breast cancer through an integrated liquid biopsy algorithm.
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Elacestrant

Following is part of Solo: you see every change to Elacestrant the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in